N. BILLERICA, Mass., Aug. 10 /PRNewswire/ -- Seahorse Bioscience, the
leading provider of tools for real-time measurement of cellular
bioenergetics in microplates, announced today that former Molecular Devices
executive Joseph Keegan has been appointed to the company's Board of
Directors. In this position, Keegan will apply his successful business
experience in the life sciences industry to accelerate the growth of
Seahorse Bioscience's novel technology for profiling cell metabolism.
"As the company moves into its next phase of growth, it will require a
strong understanding of this market," said Jay Teich, Seahorse Bioscience's
CEO. "Joe's tremendous success in building Molecular Devices, combined with
his extensive labware experience makes him an ideal addition to our Board."
Keegan brings more than 25 years of experience managing life science
tools businesses. As CEO of Molecular Devices, he developed a strategy
combining internal growth with acquisitions to build the dominant supplier
of detection solutions for drug discovery, clinical and research
applications. Keegan joined MDC from Becton Dickinson and Company where he
served as President of Worldwide Tissue Culture. Prior to Becton Dickinson,
Keegan was Vice President of Microscopy and Scientific Instruments Division
of Leica, Inc.
"Seahorse has developed a 'stethoscope for living cells.' The ability
to measure cell metabolism in a truly non-invasive way has very broad
applications," said Keegan. "Drawing on my experience with both instrument
and labware businesses, I look forward to helping Seahorse grow a
successful business in a field that I understand very well."
About Seahorse Bioscience
Seahorse Bioscience is changing cancer, obesity and diabetes drug
discovery programs the world over. Seahorse headquarters are located in
North Billerica, Massachusetts. For more information, please visit
SOURCE Seahorse Bioscience